Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
International Society for Gastrointestinal Hereditary Tumours |
RCV000075339 | SCV000106325 | pathogenic | Lynch syndrome | 2013-09-05 | reviewed by expert panel | research | Large deletion |
University of Washington Department of Laboratory Medicine, |
RCV000075339 | SCV000266079 | pathogenic | Lynch syndrome | 2015-11-20 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000075339 | SCV000563815 | pathogenic | Lynch syndrome | 2016-11-29 | criteria provided, single submitter | clinical testing | This variant is a gross deletion of the genomic region encompassing exons 16-19 of the MLH1 gene. The 5' boundary is likely confined to intron 16. The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated MLH1 protein. Loss-of-function variants including gross deletions in MLH1 are known to be pathogenic. A similar deletion has been observed in 7 unrelated individuals affected with Lynch syndrome, colon cancer and/or sebaceous skin cancer (PMID: 14635101, 16143124, 15713769). This deletion is expected to remove the most C-terminal 179 amino acids (Glu578-Cys756) from the MLH1 protein. This region includes most of the PMS2 interaction domain, which is necessary for MLH1-PMS2 dimerization and normal protein functioning (PMID: 10037723, 11292842, 20533529). For these reasons, this variant has been classified as Pathogenic. |
Mayo Clinic Laboratories, |
RCV000202024 | SCV000257061 | pathogenic | not provided | no assertion criteria provided | research |